Method for evaluating the allergen sensitivity of an individual

An allergen and sensitivity technology, applied in allergic diseases, material testing products, instruments, etc., can solve problems such as inability to measure interference

Inactive Publication Date: 2008-01-30
BIOMAY AG
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In contrast, in the article by Yuta et al., the cells were washed and, therefore, the interference of this blocking IgG could not be determined

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for evaluating the allergen sensitivity of an individual
  • Method for evaluating the allergen sensitivity of an individual
  • Method for evaluating the allergen sensitivity of an individual

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[1162] The induction of immediate symptoms of type I allergy by allergen cross-linking of effector cells (mast cells and basophils) that bind IgE antibodies is a crucial event (Ka-wakami T, et al., Nat Rev Immunol (2002) 2:773-86). As described in the classic experiment of Prausnitz and Küstner (Prausnitz C, et al., Centralbe F Bact 1 Abt Orig (1921) 86:160-8), this event is dependent on three factors, namely, allergen-specific IgE antibodies, effector cells and allergens. Since the characterization of IgE antibodies and the development of diagnostic tests capable of accurately measuring the amount of allergen-specific IgE antibodies, certain tests have studied the level of allergen-specific serum IgE antibodies and the response of allergic patients to allergens. (Stenius B et al., Clin Allergy (1971) 1:37-55; Bryant DH et al., Clin Allergy (1975) 5:145-57; Pauli G et al., Clin Allergy (1977) 7:337 -46; Bousquet J et al Clin Allergy (1987) 17:529-36; Witteman AM et al J Alle...

Embodiment 2

[1203] To determine the patient's sensitivity prior to treatment so that the correct dose can be administered, a whole blood basophil histamine release test is used. Patients with high sensitivity will receive smaller doses than patients with low sensitivity. Before treatment, dose-response curves were established using purified allergens. Simultaneously, cells are stimulated with anti-IgE to determine overall cellular sensitivity, which can affect sensitivity to allergens. The success of the treatment will usually be manageable after 4-8 weeks of treatment, after anti-allergen IgG antibodies become detectable. Because, blocking IgG antibodies may be responsible for the decreased sensitivity, it is useful to determine IgG levels for a given allergen. In addition, the dose response was again determined using purified allergen and anti-IgE. Doses giving maximal cell activation (ie maximal histamine release or CD203c upregulation) or doses determined to give some degree of act...

Embodiment 3

[1205] As described (Stahl-Skov et al. 1977. J Exp Immunol 27:432-439), no relationship between histamine release data and skin sensitivity was found when the basophil histamine release assay was performed with washed granulocyte preparations. relevance.

[1206] Histamine release can be performed using basophils from allergic patients. They were concentrated by dextran deposition, separated, washed, resuspended in histamine release buffer, and exposed to different concentrations of recombinant Bet in 96-well titer plates (TPP, Trasadingen, Switzerland) at 37°C. v1(10 -5 , 10 -4 ,, 10 -3 , 10 -2 , 10 -1 , 1 μg / ml) or anti-IgE mAbE-124-2-8 (1 μg / ml) for 30 minutes. After culturing, the cells were separated by centrifugation. The cell-free supernatant was recovered and analyzed for histamine content by using a commercial radioimmunoassay (Immunotech, Marseille, France). Histamine release was expressed as a percentage of total histamine measured in cell lysates (Valent et...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a method for evaluating the allergen sensitivity of an individual and / or the clinical efficacy of an allergen immunotherapy comprising the steps: providing at least two samples selected from the group consisting of blood or fractions thereof, connective tissue, nasal, bronchial, skin or gut biopsy material from an individual subjected or intended to be subjected to an immunotherapy with at least one pure allergen or derivative thereof, wherein the samples contain cells capable of releasing mediators in response to said allergen, contacting said sample with said allergen or derivative thereof, and determining the amounts of mediators released from said sample and evaluating the allergen sensitivity of the individual prior to therapy and / or the clinical efficacy of the immunotherapy by comparing said amounts.

Description

technical field [0001] The present invention relates to a method of monitoring the effect of allergen immunotherapy. Background technique [0002] Allergy is a dysfunction of the immune system in which an individual is allergic, developing an immune response to typically harmless substances in nature called allergens. The main antibody involved in allergic reactions is IgE. Each individual has different IgE antibodies, and each allergen stimulates its own specific IgE production. Thus, IgE antibodies that bind a defined allergen react only with that allergen. The constant region (Fc region) of IgE is capable of binding specific cellular receptors, which are capable of releasing histamine or other inflammatory mediators, cytokines and / or proteases into surrounding tissues. The cells that release histamine are mainly mast cells and basophils. The release of histamine is triggered when cell-bound IgE is contacted and cross-linked by the allergen. [0003] In particular, hi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
CPCG01N2800/24G01N33/6854A61P37/08
Inventor A·普罗希特C·梅茨-法夫尔A·韦罗特G·保利S·拉弗R·瓦伦塔N·莫特-卢克施P·瓦郎
Owner BIOMAY AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap